This study investigates whether intermittent hypoxia (IH) and physical activity (PA), either alone or in combination (simultaneously or sequentially), can improve cognitive function and brain health in middle-aged adults (50-65 years old). The hypothesis is that (1) each intervention alone (IHT or PA) provides cognitive benefits and (2) combining IHT with PA may yield additive or synergistic effects, particularly when administered simultaneously rather than sequentially. By comparing these distinct interventions, the study aims to determine which approach best preserves or enhances cognitive performance in middle-aged adults. Findings from this research may inform non-pharmacological strategies to promote healthy aging and reduce the risk of age-related cognitive decline.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Cognitive Function: Montreal Cognitive Assessment (MoCA)
Timeframe: Baseline (Week 0),Week 1 (after 3 sessions), Week 6 (post-intervention, after session 18)
Cerebral Oxygenation - Tissue Saturation Index (TSI)
Timeframe: Baseline (Week 0), Week 1 (after 3 sessions), Week 6 (post-intervention, after session 18)
Biomarker Analysis- Brain-Derived Neurotrophic Factor (BDNF) Levels
Timeframe: Baseline (Week 0), Week 1 (after 3 sessions), Week 6 (post-intervention, after session 18)
Cerebral blood flow
Timeframe: Baseline (Week 0), Week 1 (after 3 sessions), Week 6 (post-intervention, after session 18)
Cognitive Function: Stroop Test
Timeframe: Baseline (Week 0), Week 1 (after 3 sessions), Week 6 (post-intervention, after session 18)
Cognitive Function: N-Back
Timeframe: Baseline (Week 0),Week 1 (after 3 sessions), Week 6 (post-intervention, after session 18)
Cognitive Function:Operation Span Test Task
Timeframe: Baseline (Week 0),Week 1 (after 3 sessions), Week 6 (post-intervention, after session 18)
Aurélien PICHIN, Professor
Cognitive Function: The Trail Making Test
Timeframe: Baseline (Week 0), Week 1 (after 3 sessions), Week 6 (post-intervention, after session 18)
Cerebral Oxygenation - Oxyhemoglobin (Oâ‚‚Hb)
Timeframe: Baseline (Week 0), Week 1 (after 3 sessions), Week 6 (post-intervention, after session 18)
Cerebral Oxygenation - Deoxyhemoglobin (HHb)
Timeframe: Baseline (Week 0), Week 1 (after 3 sessions), Week 6 (post-intervention, after session 18)
Cerebral Oxygenation - Total Hemoglobin (tHb)
Timeframe: Baseline (Week 0), Week 1 (after 3 sessions), Week 6 (post-intervention, after session 18)
Biomarker Analysis-Vascular Endothelial Growth Factor (VEGF) Levels
Timeframe: Baseline (Week 0), Week 1 (after 3 sessions), Week 6 (post-intervention, after session 18)
Biomarker Analysis -Irisin Levels
Timeframe: Baseline (Week 0), Week 1 (after 3 sessions), Week 6 (post-intervention, after session 18)
Biomarker Analysis-Hypoxia-Inducible Factor-1 Alpha (HIF-1α) Pathway Activation
Timeframe: Baseline (Week 0), Week 1 (after 3 sessions), Week 6 (post-intervention, after session 18)